Major Drug Interaction

Can You Take Sertraline with Gabapentin?

A plain-English look at the major interaction between Sertraline (Zoloft) and Gabapentin (Neurontin) — what it means, why it happens, and what to talk to your doctor or pharmacist about.

Reviewed by , Registered Pharmacist
Last reviewed: How we research and review
Major severity AllMeds interaction database

Taking Sertraline (Zoloft) with Gabapentin (Neurontin) is a major drug interaction that should be avoided. Respiratory depression, excessive sedation, overdose. Additive CNS depression. Gabapentinoids potentiate opioid-induced respiratory depression even at therapeutic doses.

Not sure about your specific combination? Check it in the Drug Interaction Checker →

Key Takeaways

  • Interaction severity: Major
  • Risk: Respiratory depression, excessive sedation, overdose.
  • Mechanism: Additive CNS depression. Gabapentinoids potentiate opioid-induced respiratory depression even at therapeutic doses.
  • Sertraline: S4 in Australia, low risk
  • Gabapentin: S4 in Australia, moderate risk
  • Claims action: Flag for immediate prescriber review. Document intervention in claim file.

Sertraline vs Gabapentin at a Glance

Property Sertraline Gabapentin
Brand names Zoloft, Eleva 50, Setrona Neurontin, Nupentin 300, Gabapentin Sandoz
Drug class opioid gabapentinoid
Risk level low moderate
TGA Schedule (AU) S4 S4

Why Is This Combination Dangerous?

Additive CNS depression. Gabapentinoids potentiate opioid-induced respiratory depression even at therapeutic doses.

Clinical risk: Respiratory depression, excessive sedation, overdose.

Regulatory Guidance by Jurisdiction

Australia TGA / SIRA / WorkSafe

The TGA and Australian Medicines Handbook classify this as a major drug interaction requiring immediate intervention.

The TGA has issued safety communications about the risk of respiratory depression when gabapentinoids are combined with opioids. WorkSafe Victoria Drugs of Dependence Guidelines require monitoring for this combination.

United Kingdom NICE / MHRA / FPM

The MHRA has issued Drug Safety Updates warning about the risk of respiratory depression and death when gabapentinoids are combined with opioids. NICE CG173 (Neuropathic Pain) recommends gabapentinoids as monotherapy, not in combination with opioids.

United States FDA / CDC / State WC

The FDA has added warnings to gabapentinoid labels about serious breathing difficulties when taken with opioids. The CDC opioid guidelines recommend caution with concurrent CNS depressant use. Some state formularies require prior authorization for this combination.

What Claims Professionals Should Do

  1. Flag immediately as a high-risk prescribing pattern in the claim file
  2. Request urgent prescriber review with documented clinical justification for the combination
  3. Consider an independent medical examination if the prescriber cannot provide adequate justification
  4. Assess work capacity impact as the combination significantly increases sedation and impairment risk
  5. Document all interventions for audit trail and compliance purposes
  6. Check Reasonable and Necessary status for both medications against the compensable injury

Clinical reference

Moderate Guideline-supported

A clinical summary of Sertraline and Gabapentin drawn from regulator advisories, national guidelines, and authoritative drug references. Read this if you want the deeper clinical picture before talking to your prescriber or pharmacist.

Severity assessment

Moderate. This classification is driven by the increased risk of central nervous system (CNS) depression, hyponatremia, and potential for reduced seizure control when gabapentin and sertraline are used concurrently [1] [2].

Mechanism (plain English)

Both gabapentin and sertraline can affect the brain and nervous system. Gabapentin works by calming overactive nerve signals, which can lead to drowsiness and dizziness. Sertraline, an antidepressant, increases the levels of a chemical called serotonin in the brain, which helps improve mood but can also cause side effects like drowsiness and, in some cases, lower sodium levels in the blood. When taken together, these effects can be amplified. The combined use can increase the risk of excessive drowsiness, dizziness, and problems with coordination. Additionally, sertraline can, in rare instances, trigger seizures in individuals who are prone to them, which might counteract the seizure-controlling effects of gabapentin [1] [2].

Evidence level

Guideline-supported. The interaction is recognized and described in clinical drug interaction databases and guidelines [1] [2].

Top regulator advisories (cite verbatim or close paraphrase)

  • TGA (Australia): No specific public advisory found for the gabapentin + sertraline interaction. However, the product information for gabapentin (e.g., GABAPENTIN-WGR) and sertraline (e.g., ZOLOFT) details their individual side effects, including CNS depression for gabapentin and hyponatremia and seizure risk for sertraline, which contribute to the interaction [3] [4].
  • MHRA / NICE (UK): The NICE British National Formulary (BNF) indicates that both sertraline and gabapentin have effects on the central nervous system (CNS) and can cause sedation. It also notes that both can increase the risk of hyponatremia [2].
  • FDA (US): No specific advisory directly addressing the gabapentin + sertraline interaction was found. However, FDA labels for gabapentin (Neurontin) warn about somnolence, dizziness, and suicidal thoughts/behavior [5]. The FDA label for sertraline (Zoloft) warns about serotonin syndrome, increased risk of bleeding, activation of mania/hypomania, seizures, and hyponatremia [6]. These individual warnings highlight the potential for additive adverse effects when co-administered.
  • EMA (Europe): No specific advisory for this exact drug pair was readily found in the initial search. General product information for both drugs would contain warnings about CNS depression and hyponatremia, similar to other regulatory bodies.

Clinical risk factors that elevate the danger

  • Elderly patients: Increased susceptibility to CNS depressant effects and hyponatremia [1].
  • Patients with renal impairment: Gabapentin is primarily eliminated by the kidneys, so impaired renal function can lead to higher gabapentin levels and increased side effects [5].
  • Patients with a history of seizures: Sertraline can lower the seizure threshold, potentially increasing seizure frequency in susceptible individuals [1] [6].
  • Patients with a history of hyponatremia or conditions predisposing to it: Such as those on diuretics or with dehydration, as sertraline can further lower sodium levels [1] [6].
  • Concomitant use of other CNS depressants: Including alcohol, opioids, benzodiazepines, or other sedating medications, which can exacerbate drowsiness and dizziness [1] [5].

What a patient should be told

  • Be aware of increased drowsiness and dizziness: This combination can make you feel more sleepy, dizzy, or uncoordinated. Avoid driving or operating heavy machinery until you know how these medicines affect you.
  • Watch for signs of low sodium: Symptoms like nausea, vomiting, headache, confusion, muscle weakness, or unsteadiness could mean your sodium levels are too low. Seek medical attention if you experience these.
  • Do not stop taking your medication suddenly: Especially sertraline, as this can lead to withdrawal symptoms. Always talk to your doctor or pharmacist before making any changes to your medication.
  • Discuss safer alternatives: If you are concerned about these side effects, talk to your doctor or pharmacist about whether there are other treatment options or dose adjustments that could reduce your risk.
  • Seek urgent care if: You experience a seizure, severe confusion, difficulty breathing, or feel like you might pass out.

Top 3 sources (with full citation)

  1. Drugs.com. Gabapentin + Sertraline: Can You Take Them Together? https://www.drugs.com/drug-interactions/gabapentin-with-sertraline-1147-0-2057-0.html
  2. NICE. Sertraline | Interactions - BNF. https://bnf.nice.org.uk/interactions/sertraline/
  3. U.S. Food and Drug Administration (FDA). NEURONTIN (gabapentin) capsules, tablets, oral solution. Revised: 10/2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf

Notes for the reviewing pharmacist

While the interaction between gabapentin and sertraline is generally classified as moderate, primarily due to additive CNS depression and hyponatremia risk, the potential for serotonin syndrome is a common misconception. Sertraline is a serotonergic agent, but gabapentin does not directly affect serotonin levels. Therefore, the risk of serotonin syndrome from this specific combination is theoretical and not well-supported by current evidence, unless other serotonergic agents are co-administered. However, clinicians should remain vigilant for any atypical neurological symptoms. The FDA has issued warnings regarding serious breathing difficulties with gabapentin and pregabalin, especially in patients with respiratory risk factors, which could be exacerbated by additive CNS depression from sertraline. Close monitoring of patients, particularly the elderly and those with renal impairment or respiratory compromise, is crucial. Individual patient response and careful titration are key to managing this combination safely.

Sources used in this brief (3)

Check this medication against your full medication list

Check all interactions for Sertraline and Gabapentin across your claimant's full medication list.

Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.

Related Resources

Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.